ISRCTN57305201Completed未知
Clostridium difficile - adjuvant therapy with high dose VSL#3® will shorten hospital stay and reduce relapse rates in Clostridium difficile associated diarrhoea: a multicentre double blind randomised placebo controlled trial
niversity Hospitals Bristol NHS Foundation Trust (UK)0 sites114 target enrollmentStarted: February 13, 2008Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 114
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Any consenting adult patient over the age of 18 years admitted to a Clostridium difficile Cohort Ward in either Gloucester Royal Hospital or Cheltenham General Hospital. Male and female genders will be included.
Exclusion Criteria
- •There is no upper age limit and patients with IBD will not be excluded. Apart from this, the following patients will be excluded:
- •1. Those with evidence of dilated colon on plain abdominal film on admission
- •2. Any patient known to be immunosuppressed (including those on steroids)
- •3. Any patient refusing the VSL#3® as part of their treatment regime
- •4. Patients with lactose intolerance or allergy
- •5. Any patient with a history of rheumatic heart disease or prosthetic heart valve
- •6. Any patient with a history of endocarditis
Investigators
Similar Trials
Not yet recruiting
Phase 3
Treatment of recurrent Clostridium difficile infection with fecal therapy: the FECAL trial (Fecal enema to Eliminate Clostridium difficile Associated Longstanding diarrhea)bacterial infectionschronic diarrhea1001796610004018NL-OMON30253Academisch Medisch Centrum136
Not yet recruiting
Not Applicable
A prospective study of Clostridium difficile infection and quality improvement initiative based on automatic CVRCertain infectious and parasitic diseasesKCT0005892The Catholic University of Korea, Bucheon St. Mary's Hospital200
Recruiting
Not Applicable
Clinical aspects of Clostridium difficile infection after initiation of anti tuberculous medicatioCertain infectious and parasitic diseasesKCT0000808Konyang University Hospital50
Recruiting
Not Applicable
The FECAL trial, Fecal therapy to Eliminate Clostridium difficile Associated Longstanding diarrhoea.1. Clostridium difficile<br />2. Recurrent (NLD: recidiverend)<br />3. antibiotic associated diarrhoea<br />4. diarrhoea (NLD: diarree)<br />5. feces (NLD: ontlasting)<br />6. transplantation (NLD: transplantatie).NL-OMON25892Academic Medical Center Amsterdamthe Netherlands120
Active, not recruiting
Phase 1
VANCALLO - Prevention of C. difficile infections by oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a randomized double-blind placebo-controlled trialPatients hospitalized for allogeneic hematopoietic stem cell transplantationMedDRA version: 20.0Level: PTClassification code: 10054236Term: Clostridium difficile infection Class: 100000004862CTIS2024-513490-45-00Assistance Publique Hopitaux De Paris336